Volume 4.04 | Feb 2

Cord Blood News 4.04, February 2, 2012
     In this issue: Publications | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Cord Blood News on Twitter
Evaluation of the Cell Viability of Human Wharton’s Jelly Stem Cells for Use in Cell Therapy
Investigators employed a combination of highly sensitive techniques to determine the average cell viability levels and proliferation capabilities of 10 consecutive cell passages of cultured human umbilical cord Wharton’s jelly stem cells and then used RNA microarrays to identify genes associated with changes in cell viability levels. [Tissue Eng Part C Methods] Abstract

Watch The Video: Performing CFC Assays Using MethoCult™
PUBLICATIONS (Ranked by Impact Factor of the Journal)

Costimulated Tumor-Infiltrating Lymphocytes Are a Feasible and Safe Alternative Donor Cell Therapy for Relapse after Allogeneic Stem Cell Transplantation
Researchers hypothesized that after allogeneic stem cell transplantation tumor-infiltrating donor lymphocytes could be costimulated ex vivo to preferentially activate/expand anti-tumor effectors. [Blood] Abstract

1H-NMR-Based Metabolic Profiling of Maternal and Umbilical Cord Blood Indicates Altered Materno-Fetal Nutrient Exchange in Preterm Infants
The metabolic profile in 1H nuclear magnetic resonance (NMR) spectra of plasma taken immediately after birth from umbilical vein, umbilical artery and maternal blood were recorded for mothers delivering very-low-birth-weight or normo-ponderal full-term neonates. [PLoS One] Abstract

Human Umbilical Cord Wharton’s Jelly Stem Cell (hWJSC) Extracts Inhibit Cancer Cell Growth In Vitro
Umbilical cord mesenchymal stem cells have been shown to inhibit breast cancer cell growth but it is not known whether this effect is specific to only breast cancer cells. Investigators compared the effects of hWJSC extracts (conditioned medium and cell lysate) on breast adenocarcinoma, ovarian carcinoma and osteosarcoma cells. [J Cell Biochem] Abstract

Evaluation of Nano-Biphasic Calcium Phosphate Ceramics for Bone Tissue Engineering Applications: In Vitro and Preliminary In Vivo Studies
Mesenchymal stem cells isolated from human placenta, Wharton’s jelly from umbilical cord, fetal bone marrow and adipose tissue, cultured in the presence of nanosize bioceramic particles, were monitored for osteogenic differentiation. [J Biomater Appl] Abstract

A Fatal Case of Cytomegalovirus Ventriculoencephalitis in a Mycosis Fungoides Patient Who Received Multiple Umbilical Cord Blood Cell Transplantations
Researchers report here a case involving a 28-year-old female patient with mycosis fungoides who underwent umbilical cord blood transplantation three times and developed cytomegalovirus ventriculoencephalitis. [Int J Hematol] Abstract

Comparison of Different Methods for the Isolation of Mesenchymal Stem Cells from Human Umbilical Cord Wharton’s Jelly
The aim of this study was to develop the most appropriate method for the isolation of human umbilical cord-derived mesenchymal cells. [In Vitro Cell Dev Biol Anim] Abstract

Do Your Colleagues Know What They Are Missing? Share This Newsletter Now.

Athersys Announces Positive Results of MultiStem® Clinical Trial for Hematopoietic Stem Cell Transplant Support and Prevention of Graft-Versus-Host Disease
Athersys, Inc. announced positive results from its Phase I clinical trial of MultiStem®, its cell therapy product, administered to individuals undergoing allogeneic hematopoietic stem cell transplants for the treatment of leukemia and related conditions. [Press release from Athersys, Inc. discussing research presented at the Annual American Society for Bone Marrow Transplantation Tandem Meeting, San Diego] Press Release

Charter Medical Receives CE Mark Clearance for Next Generation Cell Freeze® Cryogenic Stem Cell Storage Containers
Charter Medical, Ltd., a Lydall subsidiary, announced that it received CE Mark approval on its next generation Cell Freeze® Cryogenic Storage Containers for Hematopoietic Progenitor Cells. [Lydall, Inc.] Press Release

New Partnership Signals Better Access to Life-Saving Stem Cell Treatment for Patients
Cambridge University Hospitals NHS Foundation Trust has joined forces with Virgin Health Bank to collaborate on a range of initiatives which will improve the availability of cord blood banking and stem cell therapies for both current and future patients. The ground-breaking agreement is the first of its kind between a private cord blood bank and an NHS Foundation Trust. [Virgin Health Bank] Press Release


National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW Canadian Blood and Marrow Transplant Group – 13th Annual Conference
April 11-14, 2012
Toronto, Canada

our events page to see a complete list of events in the cord blood community.

Research and Development Technologist, hPSC Media (STEMCELL Technologies) 

Scientist – Pluripotent Stem Cells (STEMCELL Technologies)

Research Technologist, Manufacturing Sciences (STEMCELL Technologies)

Business Analyst – Product Management (STEMSOFT Software)

Laboratory Supervisor – Cellular Therapy (NewYork-Presbyterian Hospital)

Pediatric Faculty – Hematology/Oncology Stem Cell Sciences (The University of Chicago)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally:
United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Cord Blood News: Archives | Events | Contact Us